Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.
The UniverXome subsidiary was established prior to Serina's reverse merger with AgeX Therapeutics in March 2024 to own the legacy assets of the predecessor company.
AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...
Bemdaneprocel is administered by surgical transplantation into a part of the brain known as the putamen, in the hope of ...
Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's ...
University of Arizona researchers revealed that dyskinesia in Parkinson’s patients stems from a disconnect in the motor ...
The following is a summary of “Expanded and independent validation of the NoMoFA scale for Parkinson’s disease: the Italian ...
Researchers at the University of Arizona have shed light on a common and troubling side effect of long-term Parkinson’s ...
Rodent study indicates that the motor cortex becomes disconnected during episodes of involuntary and uncontrollable movements ...
In a new study, researchers from the University of Arizona looked into some of the complications experienced by people with ...
The following is a summary of “Pain in Parkinson's disease is impacted by motor complications, anxiety and sleep disturbances ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback